Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze

https://doi.org/10.1016/0014-2999(89)90811-XGet rights and content

Abstract

The effects of several 5-HT1A agonists and excitatory amino acid antagonists were compared to the standard benzodiazepines, diazepam and chlordiazepoxide (CDP) in two assays predictive of anxiolytic activity, the social interaction and elevated plus maze procedures. Indicative of anxiolytic effects the 5-HT1A agonists, buspirone, gepirone and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) all significantly increased social interaction time and open arm exploration time in the social interaction and elevated plus maze procedures, respectively. Likewise, anxiolytic activity in these assays were also produced by the competitive N-methyl-D-aspartate (NMDA) antagonists, 2-amino-5-phosphonovaleric acid (AP-5), 2-amino-7-phosphonoheptanoic acid (AP-7), 3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) and the non-competitive NMDA antagonist, (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801) while NMDA produced anxiogenic effects. Furthermore, the anxiolytic effects of these agents were of equal magnitude to the benzodiazepines. These two classes of compounds were differentiated in the yohimbine-induced seizure assay, with the NMDA antagonists dose dependently antagonizing seizures similar to the benzodiazepines while the 5-HT1A agonists were inactive. These results suggest that the 5-HT1A agonists and the NMDA antagonists may be potential non-classical anxiolytic agents with different mechanisms of action.

References (47)

  • M. Goldberg et al.

    Novel non-benzodiazepine anxiolytics

    Neuropharmacology

    (1983)
  • Y. Maurin et al.

    Inhibition by yohimbine of the calcium-dependent evoked release of [3H]GABA in rat and mouse brain slices in vitro

    European J. Pharmacol.

    (1985)
  • J. Patel et al.

    Pharmacological properties of tracazolate: A new non-benzodiazepine anxiolytic agent

    European J. Pharmacol.

    (1982)
  • Pellow et al.

    Validation of open/closed arm entries in an elevated plus-maze as a measure of anxiety in the rat

    J. Neurosci. Meth.

    (1985)
  • S. Pellow et al.

    Anxiolytic and anxiogenic drug effects on exploratory activity in a elevated plus-maze: a novel test of anxiety in rat

    Pharmacol. Biochem. Behav.

    (1986)
  • D. Stephens et al.

    Modulation of anxiety by β-carbolines and other benzodiazepine receptor ligands: Relationship of pharmacological to biochemical measures of efficacy

    Brain Res. Bull.

    (1987)
  • M.H. Thiebot

    Are serotonergic neurones involved in the control of anxiety and in the anxiolytic activity of benzodiazepines?

    Pharmacol. Biochem. Behav.

    (1986)
  • C. Van der Maelen et al.

    Inhibition serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug

    European J. Pharmacol.

    (1986)
  • M. Williams

    Molecular aspects of the action of benzodiazepine and nonbenzodiazepine anxiolytics: A hypothetical allosterical model of the benzodiazepine receptor complex

    Prog. Neuropsychopharmacol. Biol. Psyciat.

    (1984)
  • P.L. Wood et al.

    Buspirone: A potential atypical neuroleptic

    Life Sci.

    (1983)
  • C. Amrick et al.

    A comparison of the anticonflict activity of serotonin agonists and antagonists in rats

    Neurosci. Abstrr.

    (1986)
  • P.S. Bernard et al.

    CGS 9896: Agonist-antagonist benzodiazepine receptor activity revealed by anxiolytic, anticonvulsant and muscle relaxation assessment in rodents

    J. Pharmacol. Exp. Ther.

    (1985)
  • J.R. Bossier et al.

    A new method for the rapid screening of minor tranquilizers in mice

    European J. Pharmacol.

    (1968)
  • Cited by (213)

    • Biased agonism in drug discovery: Is there a future for biased 5-HT<inf>1A</inf> receptor agonists in the treatment of neuropsychiatric diseases?

      2021, Pharmacology and Therapeutics
      Citation Excerpt :

      Many studies show 5-HT1A receptor agonists to possess anxiolytic-like properties (Lacivita, Leopoldo, Berardi, & Perrone, 2008). Administration of a 5-HT1A receptor agonists, 8-OH-DPAT, buspirone, and gepirone, induces anxiolytic-like effects in rodents, as shown in the elevated plus maze and the social interaction tests (Dunn, Corbett, & Fielding, 1989). However, buspirone has contrasting effects that are dose-dependent (Collinson & Dawson, 1997; Critchley, Njung'e, & Handley, 1992; Kostowski, Dyr, Krzascik, Järbe, & Archer, 1992), explained by its effects on both types of 5-HT1A receptors.

    • The effect of 5-HT<inf>4</inf> serotonin receptors in the CA3 hippocampal region on D-AP5-induced anxiolytic-like effects: Isobolographic analyses

      2021, Behavioural Brain Research
      Citation Excerpt :

      Despite the fact that NMDA receptor density is high in cortical and limbic regions which are involved in anxiety, such as prefrontal cortex, amygdala, and hippocampus, a wide distribution throughout the brain regions can happen by both ionotropic and metabotropic glutamate receptors [8,9]. Several studies have reported the anxiolytic-like effect of NMDA receptors blockade; for example, D-AP5 (D-[−]-2-amino-5-phosphonopentanoic acid) and D-AP7 (D-[−]-2-amino-7-phosphonopentanoic acid), two competitive NMDA receptor antagonists, can decrease anxiety-related behaviors in rats [10,11]. It has been indicated that D-AP5 can induce anxiolytic, antidepressant, and antinociceptive effects [12–14].

    View all citing articles on Scopus
    View full text